Prior research in non-small-cell lung carcinoma (NSCLC) has demonstrated that high TIICs, particularly CD8+ T cells, correlate with response to anti-PD-1 therapy and predict a good prognosis in many solid cancers [27, 44, 45]. Here, CD8A is linked to non-small cell lung carcinoma.